This bill aims to amend the Code of West Virginia by introducing two new sections, 16-1-23 and 16B-3-22, which focus on the training requirements for healthcare providers regarding the use of specific drugs, progesterone and mifepristone, in pregnant women. The Office of Maternal, Child and Family Health will continue to exist and is tasked with establishing an advisory council to guide the development of training programs. These trainings will cover the scientific literature on the use of progesterone to counteract mifepristone during chemical abortions and the risks associated with chemical abortions that may lead to emergency medical care. Importantly, members of the advisory council cannot have ties to abortion industry organizations.

Additionally, the bill mandates that hospitals and similar institutions that provide gynecologic, obstetric, and emergency care ensure their licensed healthcare providers complete the specified trainings outlined in section 16-1-23. This requirement aims to enhance the knowledge and preparedness of healthcare providers in managing the complexities of pregnancy-related care, particularly in the context of chemical abortions and their potential complications.

Statutes affected:
Introduced Version: 16-1-23, 16B-3-22